Form 4 for MLYS Mineralys Therapeutics, Inc.

Accepted 2025-10-15 00:00:00 ET · period of report 2025-10-13 · accession 0001933414-25-000130 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2025-10-15	2025-10-13	MLYS	Levy Adam Scott	CFO, Sec	S - Sale	$42.01	-10.8K	116.9K	-8%	-$452.0K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-10-13	S	D	7,366	$41.90	120,257	D	—	—	(F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.1362 to $42.1300. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. (F3) Since the date of the Reporting Person's last ownership report, 5,311 shares of common stock were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.
2	Common	Common Stock	2025-10-13	S	D	3,392	$42.26	116,865	D	—	—	(F4) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.1600 to $42.3400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.